Aspira Women's Health Faces Nasdaq Delisting Warning
Ticker: AWHL · Form: 8-K · Filed: 2024-10-18T00:00:00.000Z
Sentiment: bearish
Topics: delisting, listing-standards, nasdaq
Related Tickers: ASPW
TL;DR
Nasdaq's kicking Aspira out, they're fighting back.
AI Summary
Aspira Women's Health Inc. received a notice on October 17, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Market. The company is currently evaluating the notice and its options, which may include appealing the determination.
Why It Matters
This filing signals potential delisting from the Nasdaq, which could significantly impact the company's liquidity, investor confidence, and ability to raise capital.
Risk Assessment
Risk Level: high — Failure to meet listing standards and potential delisting poses a significant threat to the company's operations and market presence.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Exchange where listing is at risk
- October 17, 2024 (date) — Date of notice
FAQ
What specific listing rule did Aspira Women's Health Inc. fail to meet?
The filing states that the company received a notice regarding failure to satisfy a continued listing rule or standard for the Nasdaq Capital Market, but does not specify the exact rule.
What are the company's immediate next steps after receiving this notice?
Aspira Women's Health Inc. is currently evaluating the notice and its options, which may include appealing the determination.
When did the company receive this notice?
The company received the notice on October 17, 2024.
What is the potential consequence of failing to meet Nasdaq's listing standards?
The potential consequence is delisting from the Nasdaq Capital Market.
Has the company previously been known by other names?
Yes, the company was formerly known as VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC, and ABIOTIC SYSTEMS.
From the Filing
0001493152-24-041561.txt : 20241018 0001493152-24-041561.hdr.sgml : 20241018 20241018160039 ACCESSION NUMBER: 0001493152-24-041561 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20241017 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20241018 DATE AS OF CHANGE: 20241018 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 241380722 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm false 0000926617 0000926617 2024-10-17 2024-10-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       Form 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024       Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter)       Delaware   001-34810   33-0595156 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   12117 Bee Caves Road , Building III , Suite 100 , Austin , Texas   78738 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: (512) 519-0400       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.   On October 17, 2024, Aspira Women’s Health Inc. (the “Company”) received written notice (the R